123312-22-1 Usage
General Description
(4-CHLOROPHENYL)(CYCLOPROPYL)METHYLAMINE is a chemical compound with the formula C10H12ClN. It is a derivative of cyclopropylamine and contains a chlorophenyl group. (4-CHLOROPHENYL)(CYCLOPROPYL)METHYLAMINE is used in organic synthesis and pharmaceutical research as a building block for the preparation of various biologically active compounds. Its chemical structure and properties make it a valuable intermediate in the production of pharmaceuticals and agrochemicals. Additionally, it has potential applications in the development of new materials and chemical processes. Overall, (4-CHLOROPHENYL)(CYCLOPROPYL)METHYLAMINE plays a crucial role in the field of chemical and pharmaceutical research due to its unique structure and reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 123312-22-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,3,1 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 123312-22:
(8*1)+(7*2)+(6*3)+(5*3)+(4*1)+(3*2)+(2*2)+(1*2)=71
71 % 10 = 1
So 123312-22-1 is a valid CAS Registry Number.
123312-22-1Relevant articles and documents
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases
Addie, Matt,Ballard, Peter,Buttar, David,Crafter, Claire,Currie, Gordon,Davies, Barry R.,Debreczeni, Judit,Dry, Hannah,Dudley, Philippa,Greenwood, Ryan,Johnson, Paul D.,Kettle, Jason G.,Lane, Clare,Lamont, Gillian,Leach, Andrew,Luke, Richard W. A.,Morris, Jeff,Ogilvie, Donald,Page, Ken,Pass, Martin,Pearson, Stuart,Ruston, Linette
supporting information, p. 2059 - 2073 (2013/05/08)
Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.
